News

31. Synowledge Announces The Launch Of Regulatory Affairs Services 7/24/2011

    Synowledge, LLC, a market leader in pharmacovigilance and related IT services for pharmaceutical and biotechnology companies, is pleased to announce the launch of its Regulatory Affairs service line.

32. IDDCR - Temple School Of Pharmacy (TUSP) Life Science - Clinical Research, Pharmacovigilance Programs To Help Industry Talent Crunch In India 7/15/2011
    International Drug Discovery and Clinical Research (IDDCR) and the prestigious Temple University’s School of Pharmacy (TUSP) have joined hands in the delivery of global certificate programs to India.
33. Phase III Trial Of Novartis Drug Afinitor Met Primary Endpoint Of Reducing SEGA Tumor Size In Patients With Tuberous Sclerosis 7/15/2011
    Novartis announced recently Phase III trial results that showed more than one-third of patients taking Afinitor (everolimus) tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC).
34. EXTEDO Introduces Hosted Version Of PcVmanager 7/15/2011
    EXTEDO, a key eRegulatory Affairs solutions provider for life sciences firms, today announced that it has introduced a hosted version of PcVmanager.
35. Novartis Drug Afinitor Met Primary Endpoint Of Phase III Study In Women With Advanced Breast Cancer 7/8/2011
    Novartis announced recently that an interim analysis of a pivotal Phase III study showed Afinitor (everolimus) tablets in combination with exemestane significantly extended progression-free survival (PFS), or time without tumor growth, when compared to placebo plus exemestane in women with advanced breast cancer.